Falls and Fracture Risk assessment and management
|
|
- Alexander Reynolds
- 7 years ago
- Views:
Transcription
1 Falls and Fracture Risk assessment and management
2 Disclosures: Although various guidelines and studies were reviewed, this represents my own personal bias and conclusions.
3 What do we know? 1) Fractures are bad, worse in the elderly, especially hip fractures. 2) There are multiple factors leading to increased fracture risk, the obvious ones being age and risk of falls. 3) There are industry funded studies that demonstrate significant fracture reduction with medications. 4) There are numerous guidelines out there BC, National, US (NOF), UK (NOGG), UK (NICE), European, Australian.
4 What do we know? 5) There are multiple fracture risk assessment tools- FRAX, QFracture, Garvan, CAROC. 6) There are significant healthcare costs involved- BMD scans, medication costs, hospitalization and physician costs not to mention quality of life issues. 7) The decision to treat lies with the patient and we need to be able to provide objective information to the patient to help guide their decision.
5 BC guidelines Osteoporosis Canada NOF NOGG NICE European Australian
6 So where do we start?
7 Basic principles
8 Fracture Risk Assessment The most studied and validated tool is the WHO FRAX tool. There is a specific Canadian cohort for the FRAX. It has its limitations, but is simpler to use than the others (fewer inputs). Despite it being a WHO tool, the formula is proprietary through the University of Sheffield and although use of the online calculator is free, to be able to use the tool on your desktop you have to pay a license fee. The tool can be used with and without a BMD value.
9 Falls Risk Assessment There are many comprehensive tools out there, most require some basic equipment and a stopwatch and look to take min to complete. However, there is one tool: Fracture Risk Assessment Tool-FRAT, that has been produced specifically for the use in a GP office and will take less than one minute.
10 Fracture risk reduction Probably the basic interventions are the most important interventions: 1) Encourage maintaining an active lifestyle and include activities to improve leg strength and balance: 30-60min of walking per day. 2) Encourage proper technique when lifting: keep your back straight rather than bent. Also, consider whether the object to be lifted can be divided into smaller portions before lifting. 3) Ensure adequate daily intake of both calcium (generally about total mg/day) and vitamin D (about 1000 IU/day).
11 4) Reduce risk for falls: Having a fall is the single greatest risk for breaking a bone. a) Review medications regularly Polypharmacy (greater than 3 medications) is independent risk factor Common culprits OR Percentage increase Antidepressants % Antipsychotics % Benzodiazepines % Sedatives % Antihypertensive % NSAID % Diuretics % B-Blockers % Narcotics (CI ) Woolcott J., Richardson K., Wiens M., Patel B., Marin J., Khan K., et al.. (2009) Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med 169: b) Encourage regular vision checks. c) Consider home assessment for the high risk patient by the FHA Mobile Falls Prevention team.
12 5) Medications to strengthen bones: Commonest used in general practice are the bisphosphonate group. Bisphosphonates target the areas of higher bone turnover. The osteoclast cells absorb the bisphosphonate drug, which slows down their activity and reduces bone break down. There are several different types of bisphosphonates, and they each work slightly differently. We know that they can Interfere with the formation of osteoclasts Make osteoclasts self destruct, or die early Change the signalling between osteoclasts and osteoblasts Form a barrier between the bone and the osteoclast
13
14 Tolerability of bisphosphonates: GIT adverse effects Results: A total of 11% of the alendronate patients and 13% of the placebo patients reported an upper GI tract adverse event. Discontinuations due to drug-related upper GI tract adverse events occurred in 3% of alendronate patients and 1% of placebo patients. Results: Of 438 patients who were randomized, 367 completed the study. The proportions of patients who experienced an upper GI AE during the study period were 66 (22.7%) and 30 (20.4%) for alendronate vs placebo. Renal impairment Both oral and intravenous bisphosphonates are not recommended when egfris < 30 (<35 for IV).
15 Some of the rare serious side effects: Osteonecrosis of the jaw It has been estimated that the risk of ONJ is approximately 1 in 10,000 to 1 in 100,000 patient-years in patients taking oral bisphosphonates for osteoporosis. Atypical Femur Fractures Although long-term use (median treatment seven years) of bisphosphonates increases the RR of atypical fractures, the absolute risk is low (3.2 to 50 cases per 100,000 person-years). The risk may rise with duration of bisphosphonate exposure (100 per 100,000 person-years). When bisphosphonates are stopped, the risk of atypical fracture declines.
16 There are many industry sponsored trials. I have reviewed the FIT,VERT-NA and HORIZON trials as these appear to be the original trials of note for bisphosphonates:
17 A single, annual intravenous (IV) infusion of zoledronic acid can decrease the risk of vertebral fracture by 70% and the risk of hip fracture by 41% among women with osteoporosis, according to the 3-year results of the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON) Pivotal Fracture Trial. The results were published in the New England Journal of Medicine (NEJM).
18 HORIZON Trial (Aclasta/Zoledronic acid) 7765 women 65-89yrs (mean 73yrs) over 3 yrs Tscore < -2.5 or Tscore <-1.5 and vertebral fracture Morphometric vertebral #: 3.3% cf 10.9% RRR 70% ARR 7.6% Hip fracture: 1.4% cf 2.5% RRR 41% ARR 1.1%
19 FIT trial Sponsor Merck Research Laboratories 3658 Women aged 55-80yrs Average age 70yrs Alendronate 5mg daily increased to 10mg daily plus 500mg Ca and 250iu Vit D Femoral neck T-score <-2.5 or previous vertebral fracture 3-4 yrs of treatment, effect noted within 12 months Fracture reduction: RRR ARR Hip 53% 1.2% Vertebral (radiological) 48% 7.2% Vertebral (clinical) 45% 2.3% All fractures 30% 5.5%
20 VERT-NA Residronate - Procter & Gamble Started with 2458 women <85yrs All had vertebral fracture seen on screening Xray Average age 70yrs Ended up with 949 women, 3 years of treatment Residronate 5mg daily plus Ca 1000mg and up to 500iu Vit D if indicated Fracture reduction: RRR ARR Vertebral(radiological) 41% 4% Non vertebral 39% 3.2%
21 Summary based on these trials: For females around age of 70yrs with either a prior vertebral fracture or a BMD < -2.5 (ie evidence of osteoporosis), taking a bisphosphonate will reduce the: ABSOLUTE risk of Hip fractures by about 1% Vertebral (clinical) fractures by about 2% All fractures (include radiological) by about 5%. Most guidelines focus on the RRR (53%/45%/30%) and then apply these numbers to the risk calculated by the FRAX tool (10yr predication) which leads to some interesting results.
22 Cochrane review of fracture risk prevention with bisphosphonates: Note that their definition of secondary prevention includes patient with low bone mass. ionid= a a0b.f01t02
23 Goals of this Fracture Risk Assessment Tool 1) To facilitate appropriate screening of patients for increased fall and fracture risk. 2) Use these results to remind us to address the various physical and polypharmacy issues. 3) Provide meaningful information to present to the patient to aid in their decision making if they are considering bone building medications.
24 Lets look at some numbers from our clinic..
25 Number of patients in clinic over the age of 50 yrs: 2472 (>65yrs 1267) Number of patients in clinic on bisphosphonates: million Canadians suffer from osteoporosis One in four women over the age of 50 has osteoporosis One in eight men over the age of 50 has osteoporosis 70 per cent of hip fractures are related to osteoporosis Up to 20 per cent of hip fractures result in death Up to 50 per cent of hip fractures result in permanent disability More women die each year as a result of osteoporotic fractures than from breast and ovarian cancer combined
26 Results for females screened in last month with the new tool Hip Fracture Risk Total Fracture Risk Age 18% 38% 89 63% 65% % 24% 85 13% 35% % 22% 83 11% 32% 82 16% 35% % 19% % 16% % 18% 80 29% 41% % 17% % 14% % 15% % 17% % 13% % 12% % 16% % 11% % 9% 67 Averages 11% 29% 78.9
27 Results for males screened in last month Hip Fracture Risk Total Fracture Risk Age 6.40% 11% % 8.90% % 10% % 7.80% 83 19% 26% % 13% % 8.10% % 5.40% % 7.50% % 17% 66 Averages 6% 11% 81.3
28
29 Lets apply some guidelines.
30 BC Guidelines
31 NOF (USA) Guidelines Pharmacologic treatment recommendations: Initiate pharmacologic treatment in those with hip or vertebral (clinical or asymptomatic) fractures. Initiate therapy in those with T-scores < -2.5 at the femoral neck, total hip or lumbar spine by dual-energy x-ray absorptiometry (DXA). Initiate treatment in postmenopausal women and men age 50 and older with low bone mass (T-score between -1.0 and -2.5, osteopenia) at the femoral neck, total hip or lumbar spine by DXA and a 10-year hip fracture probability > 3 percent or a 10-year major osteoporosisrelated fracture probability > 20 percent based on the U.S.-adapted WHO absolute fracture risk model (FRAX ; and
32 NICE (UK) Guidelines Alendronate is recommended as a treatment option for the primary prevention of osteoporotic fragility fractures in the following groups: Women aged 70years or older who have an independent clinical risk factor for fracture or an indicator of low BMD and who are confirmed to have osteoporosis (that is, a T-score of 2.5SD or below). Women aged 65 69years who have an independent clinical risk factor for fracture and who are confirmed to have osteoporosis (that is, a T-score of 2.5SD or below). Postmenopausal women younger than 65years who have an independent clinical risk factor for fracture and at least one additional indicator of low BMD and who are confirmed to have osteoporosis (that is, a T-score of 2.5SD or below).
33 NOGG Executive Men and women with probabilities below the lower assessment threshold can be reassured. Men and women with probabilities above the upper assessment threshold can be considered for treatment. Men and women with probabilities between the upper and lower assessment threshold should be referred for bone mineral density measurements and their fracture probability reassessed.
34 Guideline outcomes Total = 20 Females Guideline BMD Nothing Rx w/o BMD?Final Rx?????? BC NOF (US) NICE (UK) NOGG (UK) Modified NOGG
35 Modified NOGG Below intervention threshold reassure Equal or above intervention threshold do BMD first and consider treatment if remains equal or above the intervention threshold and femoral neck Tscore <
36 All Wales Medicine Strategy Group Evidence shows that the patients most likely to benefit from treatment with bisphosphonates are women who have already been diagnosed with low BMD or have already had a vertebral fracture. The number of patients that are needed to treat (NNT)in order to avoid a vertebral or hip fracture is given in Table 1. Table 1. NNTs for alendronate plus calcium/vitamin D taken from NHS Highland s Guidance for prescribing in frail adults. Age 2-year vertebral # (NNT) 2-year hip # (NNT) years years years years years For example if 65 patients aged between 70 and 74 years take alendronate plus calcium/vitamin D for 2 years, 1 vertebral fracture will be avoided.
37
38
39 Logic incorporated in the tool: 1) Screen females > 65 yrs and males >75 yrs with FRAX without BMD Repeat screening every 5yrs to age 75 then every 3 yrs to age 85 then every 2 yrs thereafter. 2) Modified NOGG thresholds used to decide on need for BMD and based on the BMD results (both the calculated total fracture risk as well as the femoral neck Tscore), the need for medication. 3) Threshold of 2o% is used to recommend a falls prevention program to all ages.
40 Final Conclusions Fractures are a significant medical problem particularly in the aging population. There are multiple risk factors for increasing fracture risk, especially important are falls and lifestyle (exercise, smoking, alcohol, caffeine). Bone building medications have a place but the data is incomplete so decisions need to be made on Expert opinion and simple common sense.
41 FRAX based guidelines: Is a universal model appropriate?
42 GPSC Fee code Personal Health Risk Assessment Eligible population must have one of four risks: Smoking Dx 786 Obesity (BMI >30 ) Dx783 Unhealthy Eating Dx 783 Inadequate Exercise Dx 785 INTENT: Risk assessment & planning visit both for identified risks & to review relevant recommended prevention services based on age, sex and gender (eg. Pap, mammogram, stool OB, immunizations, etc.)
43 The End
Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC
Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with
More informationOsteoporosis has been identified by the US Surgeon General
New Guidelines for the Prevention and Treatment of Osteoporosis E. Michael Lewiecki, MD, and Nelson B. Watts, MD Abstract: The World Health Organization Fracture Risk Assessment Tool (FRAX ) and the National
More informationPROTOCOL FOR PATIENTS WITH ABNORMAL LAB AND X-RAY VALUES
PROTOCOL FOR PATIENTS WITH ABNORMAL LAB AND X-RAY VALUES Patients newly diagnosed as osteopenic or osteoporotic on a radiology report or patients receiving abnormal lab values on the following lab tests
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) OSTEOPOROSIS GUIDELINE
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) OSTEOPOROSIS GUIDELINE This is an updated guideline It incorporates the latest NICE guidance There are strong recommendations for calcium + vitamin D
More informationWhat You Need to Know for Better Bone Health
What You Need to Know for Better Bone Health A quick lesson about bones: Why healthy bones matter The healthier your bones The more active you can be Bone health has a major effect on your quality of life
More informationDrug treatment pathway for Osteoporosis in Postmenopausal Women
Drug treatment pathway for Osteoporosis in Postmenopausal Women Version 1.0 Ratified by: East Sussex HEMC Date ratified: 26.01.2011 Job title of originator/author Gillian Ells, East Sussex HEMC Pharmacist
More informationCystic fibrosis and bone health
Cystic fibrosis and bone health Factsheet March 2013 Cystic fibrosis and bone health Introduction As we get older our bones become thinner and weaker, and may become more susceptible to fracture. However
More informationOsteoporosis Assessment Using DXA and Instant Vertebral Assessment. Working Together For A Healthier Community
Osteoporosis Assessment Using DXA and Instant Vertebral Assessment Working Together For A Healthier Community Osteoporosis The Silent Thief The Facts About Osteoporosis 1 in 2 women will develop osteoporosis
More informationOsteoporosis Update. Laura E. Ryan, MD
Osteoporosis Update Laura E. Ryan, MD Assistant Director for Special Programs Center for Women s Health Clinical Assistant Professor of Medicine Division of Endocrinology, Diabetes and Metabolism The Ohio
More informationNATIONAL OSTEOPOROSIS FOUNDATION OSTEOPOROSIS CLINICAL UPDATES Rehabilitation of Patients With Fragility-Related Fractures CE APPLICATION FORM
NATIONAL OSTEOPOROSIS FOUNDATION OSTEOPOROSIS CLINICAL UPDATES Rehabilitation of Patients With Fragility-Related Fractures CE APPLICATION FORM First Name: Last Name: Mailing Address: City: State: Zip/Postal
More informationFRAX Identifying people at high risk of fracture
FRAX Identifying people at high risk of fracture WHO Fracture Risk Assessment Tool, a new clinical tool for informed treatment decisions Authored by Dr. Eugene McCloskey International Osteoporosis Foundation
More informationTreating Osteoporosis WITH BISPHOSPHONATES
Treating Osteoporosis WITH BISPHOSPHONATES Who is SIGMA? SIGMA is the Canadian Menopause Society. We are professionals specialized in different areas of post-menopausal women s health care, including family
More informationHow To Take A Bone Marrow Transplant
Drug treatments to protect your bones This information is an extract from the booklet, Bone health. You may find the full booklet helpful. We can send you a copy free see page 5. Contents Bisphosphonates
More informationBONE MINERAL DENSITOMETRY REPORTING
CAR TECHNICAL STANDARDS FOR BONE MINERAL DENSITOMETRY REPORTING APPROVED: JANUARY 25, 2013 KERRY SIMINOSKI, MD, FRCPC; MARGARET O'KEEFFE, MD, FRCPC; JACQUES P. BROWN, MD, FRCPC; STEVEN BURRELL, MD, FRCPC;
More informationClinical Policy Guideline
Clinical Policy Guideline Policy Title: Bone Density Testing Policy No: B0215A.00 Effective Date: 01/01/15 Date Reviewed: 03/25/15 I. DEFINITION/BACKGROUND Bone density testing is used to estimate the
More informationBone Basics National Osteoporosis Foundation 2013
When you have osteoporosis, your bones become weak and are more likely to break (fracture). You can have osteoporosis without any symptoms. Because it can be prevented and treated, an early diagnosis is
More informationClinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada: Background and Technical Report
Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada: Background and Technical Report Authors: Alexandra Papaioannou MD MSc 1, Suzanne Morin MD MSc 2, Angela M. Cheung
More informationSIGMA sums it up: Answers to questions about osteoporosis and denosumab therapy
SIGMA sums it up: Answers to questions about osteoporosis and denosumab therapy Table of contents Who is SIGMA? Frequently asked questions we will address: 1. What is osteoporosis? 2. Why is it important
More informationFast Facts on Osteoporosis
Fast Facts on Osteoporosis Definition Prevalence Osteoporosis, or porous bone, is a disease characterized by low bone mass and structural deterioration of bone tissue, leading to bone fragility and an
More informationPRACTICAL DENSITOMETRY
PRACTICAL DENSITOMETRY The Challenge of Osteoporosis Osteoporosis is a silent disease that develops over decades Goal: identify patients with osteoporosis before fractures occur Means: measure bone density
More information2-1. Osteoporose. Dr. P. Van Wettere Radiologie en medische beeldvorming
2-1 Osteoporose Dr. P. Van Wettere Radiologie en medische beeldvorming 2-2 Osteoporose Definitie Incidentie, mortaliteit, morbiditeit, kost Diagnose Radiologie Botdensitometrie FRAX FractureCascade History
More informationOsteoporosis Clinical guideline for prevention and treatment
Osteoporosis Clinical guideline for prevention and treatment Executive Summary Updated November 2014 National Osteoporosis Guideline Group on behalf of the Bone Research Society, British Geriatrics Society,
More informationClinical Practice Guideline for Osteoporosis Screening and Treatment
Clinical Practice Guideline for Osteoporosis Screening and Treatment Osteoporosis is a condition of decreased bone mass, leading to bone fragility and an increased susceptibility to fractures. While osteoporosis
More informationOsteoporosis Medications
Osteoporosis Medications When does a doctor prescribe osteoporosis medications? Healthcare providers look at several pieces of information before prescribing a bone- preserving or bone- building medication.
More informationBULLETIN. Slovak Republic Ministry of Health
BULLETIN Slovak Republic Ministry of Health Part 51-53 November 13, 2009 No. 57 CONTENTS: 52. Slovak Republic Ministry of Health Guidelines for the Diagnosis of Glucocorticoidinduced Osteoporosis 52. Slovak
More information16. ARTHRITIS, OSTEOPOROSIS, AND CHRONIC BACK CONDITIONS
16. ARTHRITIS, OSTEOPOROSIS, AND CHRONIC BACK CONDITIONS Goal Reduce the impact of several major musculoskeletal conditions by reducing the occurrence, impairment, functional limitations, and limitation
More informationOrthopaedic Issues in Adults with CP: If I Knew Then, What I Know Now
Orthopaedic Issues in Adults with CP: If I Knew Then, What I Know Now Laura L. Tosi, MD Director, Bone Health Program Children s National Medical Center Washington, DC Epidemiology 87-93% of children born
More informationSIGN 142 Management of osteoporosis and the prevention of fragility fractures. A national clinical guideline March 2015. Evidence
SIGN 142 Management of osteoporosis and the prevention of fragility fractures A national clinical guideline March 2015 Evidence KEY TO EVIDENCE STATEMENTS AND ECOMMENDATIONS LEVELS OF EVIDENCE High-quality
More informationOsteoporosis. Drugs to prevent bone fractures in people with: Contents. 2: Our Recommendations. 3: Welcome. 6: Who Needs Drugs to Prevent Fractures?
Drugs to prevent bone fractures in people with: Osteoporosis Comparing Effectiveness, Safety, and Price Contents 2: Our Recommendations 3: Welcome 6: Who Needs Drugs to Prevent Fractures? 8: Choosing a
More informationBISPHOSPHONATE RELATED OSTEONECROSIS OF THE JAW (BRONJ) BISPHOSPHONATES AND WHAT HAPPENS TO BONE VINCENT E. DIFABIO, DDS, MS MEMBER OF THE COMMITTEE ON HEALTHCARE AND ADVOCACY FROM THE AMERICAN ASSOCIATION
More informationTreatment of Myeloma Bone Disease
Treatment of Myeloma Bone Disease James R. Berenson, MD Medical & Scientific Director Institute for Bone Cancer & Myeloma Research West Hollywood, CA Clinical Consequences of Myeloma Bone Disease Pathological
More informationProlia 2 shots a year proven to help strengthen bones.
Ask your doctor if Prolia (denosumab) is right for you and visit us at www.prolia.com For women with postmenopausal osteoporosis at high risk for fracture: there s Prolia. Prolia 2 shots a year proven
More informationSUMMARY OF THE RISK MANAGEMENT PLAN (by medicinal product)
PART VI SUMMARY OF THE RISK MANAGEMENT PLAN (by medicinal product) Format and content of the summary of the RMP The summary of the RMP part VI contains information based on RMP modules SI, SVIII and RMP
More informationMedications for Prevention and Treatment of Osteoporosis
1 Medications for Prevention and Treatment of Osteoporosis Osteoporosis is a disease where the strength of bones is less than normal, making them more susceptible to fracture, or breaking, than normal
More informationBone Disease in Myeloma
Bone Disease in Myeloma Boston, Massachusetts Saturday, July 26, 2008 Brian G.M. Durie, M.D. Bone Disease in Myeloma Lytic Lesions Spike Bone Marrow Plasma Cells Collapse of Vertebrae Biology of Myeloma
More informationCare pathways for vertebral compression fractures
Care pathways for vertebral compression fractures SYDNEY MEDICAL SCHOOL Associate Professor Manuela L Ferreira, PhD Sydney Medical Foundation Fellow Institute of Bone and Joint Research and The George
More informationBone Densitometry. What is a Bone Density Scan (DXA)?
Scan for mobile link. Bone Densitometry Bone densitometry, also called dual-energy x-ray absorptiometry or DEXA, uses a very small dose of ionizing radiation to produce pictures of the inside of the body
More informationCost Effectiveness Estimate of Bazedoxifene
Article ID: WMC002547 2046-1690 Cost Effectiveness Estimate of Bazedoxifene Corresponding Author: Dr. Ana A Iglesias, pharmacist, Pharmacy Department - Hospital of Manacor - Spain Submitting Author: Dr.
More informationDrug treatments for osteoporosis
Drug treatments for osteoporosis What is osteoporosis? Osteoporosis occurs when the struts which make up the mesh-like structure within bones become thin causing them to become fragile and break easily,
More informationBone Disease in Myeloma
Bone Disease in Myeloma Washington, DC August 8, 2009 Brian G.M. Durie, M.D. Bone Disease in Myeloma Lytic Lesions Spike Bone Marrow Plasma Cells Collapse of Vertebrae Biology of Myeloma Vascular Cytokines
More informationEuropean guidance for the diagnosis and management of osteoporosis in postmenopausal women
DOI 10.1007/s00198-012-2074-y POSITION PAPER European guidance for the diagnosis and management of osteoporosis in postmenopausal women J. A. Kanis & E. V. McCloskey & H. Johansson & C. Cooper & R. Rizzoli
More informationOSTEOPOROSIS -Medical Management of Men and Women who have (or are at risk of ) Osteoporosis
Basingstoke, Southampton and Winchester District Prescribing Committee OSTEOPOROSIS -Medical Management of Men and Women who have (or are at risk of ) Osteoporosis Frail, increased fall risk + housebound
More informationOsteoporosis Medicines and Jaw Problems
Osteoporosis Medicines and Jaw Problems J. Michael Digney, D.D.S. Osteoporosis is a condition that affects over 10 million patients in this country, with the majority of those being post-menopausal women.
More informationThe Role of Bisphosphonates in Multiple Myeloma: 2007 Update Clinical Practice Guideline
The Role of Bisphosphonates in Multiple Myeloma: 2007 Update Clinical Practice Guideline Introduction ASCO convened an Update Committee to review and update the 2002 recommendations for the role of bisphosphonates
More informationYour Future by Design
Retirement Research Series Your Future by Design Health, money, retirement: The different needs of men and women This research report is one of several reports in the Your Future by Design Retirement Research
More informationBone Disease in Myeloma. St. Petersburg, Russia September 16, 2009
Bone Disease in Myeloma St. Petersburg, Russia September 16, 2009 Bi Brian G.M. GMDurie, M.D. MD Bone Disease in Myeloma Lytic Lesions Spike Bone Marrow Plasma Cells Collapse of Vertebrae Biology of Myeloma
More informationCampaign toolkit for health professionals and policy makers. October 2013
Campaign toolkit for health professionals and policy makers October 2013 Contents 1. About the campaign 3 2. Campaign messages 4 3. How to get involved 5 4. What to use 6 5. Healthcare information 7 6.
More informationA Treatment Algorithm for Indian Patients of Osteoporosis
Indian Medical Gazette FEBRUARY 2012 67 Symposia Update A Treatment Algorithm for Indian Patients of Osteoporosis Shailendra Mohan Lakhotia, Senior Consultant Orthopedic Surgeon, Kolkata 700 045. Prashant
More informationScans and tests and osteoporosis
Scans and tests and osteoporosis What is osteoporosis? Osteoporosis occurs when the struts which make up the mesh-like structure within bones become thin causing them to become fragile and break easily,
More informationHow To Choose A Biologic Drug
North Carolina Rheumatology Association Position Statements I. Biologic Agents A. Appropriate delivery, handling, storage and administration of biologic agents B. Indications for biologic agents II. III.
More informationHealthy Aging Lab: Current Research Abstracts
Healthy Aging Lab: Current Research Abstracts Arsenic Exposure and Women s Health Environmental exposure to inorganic arsenic is an indisputable source of increased risk of several human cancers and chronic
More informationTrans people and osteoporosis
Trans Care Medical issues Trans people and osteoporosis What is Osteoporosis? Osteo means bone, and porosis means porous or sponge-like. Osteoporosis refers to bones becoming less dense and more spongy.
More informationHow To Treat Osteoporosis
Treatment Guidelines for Osteoporosis in Adults. Background Osteoporosis is a condition characterised by a reduction in bone mass density increasing the risk of fracture. Fractures occur most commonly
More informationObjectives. Osteoporosis a major public health threat. Bone-Up on Osteoporosis Update 2011
Bone-Up on Osteoporosis Update 2011 3/30/11 Kristine Olson, MS, APN, FNP-BC Nurse Practitioner Mercer Bucks Hematology Oncology 1 Objectives Review risk factors and screening for osteoporosis. Describe
More informationOsteoporosis Treatments That Help Prevent Broken Bones. A Guide for Women After Menopause
Osteoporosis Treatments That Help Prevent Broken Bones A Guide for Women After Menopause June 2008 fast facts Medicines for osteoporosis (OSS-tee-oh-puh-ROW-sis) can lower your chance of breaking a bone.
More informationMargaret French, Specialist Nurse, Fracture Liaison Service Glasgow Royal Infirmary Rachel Lewis Rheumatology Specialist Physiotherapist, North
Margaret French, Specialist Nurse, Fracture Liaison Service Glasgow Royal Infirmary Rachel Lewis Rheumatology Specialist Physiotherapist, North Bristol NHS Trust Very informal workshop to facilitate discussion
More informationRecent Topics in Treatment of Osteoporosis
Review Article Recent Topics in Treatment of Osteoporosis JMAJ 49(9 10): 309 314, 2006 Satoshi Soen* 1 Abstract It has come to light that osteoporosis-related fractures are more critical than previously
More informationHealthy Bones For Life PATIENT S GUIDE
Healthy Bones For Life PATIENT S GUIDE Contents Healthy Bones for Life Patient s Guide INTRODUCTION Healthy Bones for Life... 3 SECTION 1 How Bones Change and Grow... 5 SECTION 2 Strong Bones are Important
More informationPreventive Care Guideline for Asymptomatic Elderly Patients Age 65 and Over
Preventive Care Guideline for Asymptomatic Elderly Patients Age 65 and Over 1. BMI - Documented in patients medical record on an annual basis up to age 74. Screen for obesity and offer counseling to encourage
More informationOSTEOPOROSIS REHABILITATION PROGRAM
OSTEOPOROSIS REHABILITATION PROGRAM Tricia Orme, R.N. BSc(N) Mary Pack Arthritis Program Victoria i Arthritis i Centre Objectives Participants will gain an understanding of what Osteoporosis is and how
More informationDoes chronic lymphocytic leukemia increase the risk of osteoporosis?
Does chronic lymphocytic leukemia increase the risk of osteoporosis? Amrita Desai, MD Internal Medicine Residency Program Adam Olszewski, MD Department of Hematology and Oncology Memorial Hospital of Rhode
More informationOSTEOPOROSIS. Case study 69 report. October 2011
OSTEOPOROSIS Case study 69 report October 2011 Independent, not-for-profit and evidence based, NPS enables better decisions about medicines and medical tests. We are funded by the Australian Government
More informationPreventive Care Guideline for Asymptomatic Low Risk Adults Age 18 through 64
Preventive Care Guideline for Asymptomatic Low Risk Adults Age 18 through 64 1. BMI - Documented in patients medical record on an annual basis. Screen for obesity and offer intensive counseling and behavioral
More informationOral Bisphosphonate and Risk of Esophageal Cancer: A Nationwide Claim Study
J Bone Metab 2015;22:77-81 http://dx.doi.org/10.11005/jbm.2015.22.2.77 pissn 2287-6375 eissn 2287-7029 Original Article Oral Bisphosphonate and Risk of Esophageal Cancer: A Nationwide Claim Study Gi Hyeon
More informationPress Information. Vitamin D deficiency
DSM, Corporate Communications P.O. Box 6500, 6401 HJ Heerlen The Netherlands phone +31 (0) 45 578 2421 www.dsm.com Vitamin D is one of the essential nutrients for human health. Unlike other types of vitamins
More informationHormones and Healthy Bones
Hormones and Healthy Bones Helping Midlife Women Make Better Choices for a Healthy Future 1 Hormones and Healthy Bones helps midlife women make better choices for a healthy future. Midlife women are the
More informationNATIONAL OSTEOPOROSIS FOUNDATION OSTEOPOROSIS CLINICAL UPDATES Vitamin D and Bone Health CE APPLICATION FORM
NATIONAL OSTEOPOROSIS FOUNDATION OSTEOPOROSIS CLINICAL UPDATES Vitamin D and Bone Health CE APPLICATION FORM First Name: Last Name: Mailing Address: City: State: Zip/Postal Code: Country: Phone Number:
More informationOsteoporosis. Dr Gordon MacDonald BSc MB BChir MRCP Consultant Rheumatologist. Rheumatology and Arthritis Seminar Tuesday 5 th February 2013
Osteoporosis Dr Gordon MacDonald BSc MB BChir MRCP Consultant Rheumatologist Rheumatology and Arthritis Seminar Tuesday 5 th February 2013 Plan What is osteoporosis? Consequences of osteoporosis Risk factors
More informationThe menopausal transition usually has three parts:
The menopausal transition usually has three parts: Perimenopause begins several years before a woman s last menstrual period, when the ovaries gradually produce less estrogen. In the last 1-2 years of
More informationProposed Changes to Existing Measure for HEDIS 1 2015: Osteoporosis Management in Women Who Had a Fracture (OMW)
Draft Document for HEDIS 2015 Public Comment Obsolete After March 19, 2014 1 Proposed Changes to Existing Measure for HEDIS 1 2015: Osteoporosis Management in Women Who Had a Fracture (OMW) NCQA seeks
More informationTreatment of osteoporosis in fragility fractures
Orthogeriatrics Clinical Summary Document Treatment of osteoporosis in fragility fractures Fragility fractures are extremely prevalent in older adults with a staggering cost of treatment. As the population
More informationNHS GGC Vitamin D Supplementation Frequently asked Questions
Pharmacy & Prescribing Support Unit NHS GGC Vitamin D Supplementation Frequently asked Questions In February 2012 the Scottish Government issued advice on supplements for groups at risk of vitamin D deficiency.
More informationHormone therapy and breast cancer: conflicting evidence. Cindy Farquhar Cochrane Menstrual Disorders and Subfertility Group
Hormone therapy and breast cancer: conflicting evidence Cindy Farquhar Cochrane Menstrual Disorders and Subfertility Group The world of hormone therapy in the 1990 s Throughout the 1970s, 1980s and 1990s
More informationCa : methods for determining DRIs. Adults. 4average requirement, meta-analyzed balance studies by FAO/WHO :
Minerals Categories of Ds for Minerals - Ca, P, Na, Cl, K, Mg - Mineral Ca RDA P Ca ; 서울대학교 이연숙 Na P ; 국민대학교 김선희 Na, Cl ; 동의대학교 임화재 K ; 국민대학교 장문정 Mg ; 인하대학교 천종희 Cl K Mg Indicators for Estimating Ds Ca
More informationOsteoporosis in elderly: prevention and treatment
Clin Geriatr Med 18 (2002) 529 555 Osteoporosis in elderly: prevention and treatment Manish Srivastava, MD a, Chad Deal, MD b, * a Section of Geriatric Medicine, A91 Cleveland Clinic Foundation, 9500 Euclid
More informationVitamin D Deficiency in Older Patients
Fourth Year Medical Students Required Written Patient Care Assignments Reflecting Awareness of Use of Vitamin D in Older Patients at Risk for Falling John Agens, M.D. Associate Professor in Geriatrics
More informationDrug-Induced Osteoporosis
Drug-Induced Osteoporosis By Susan K. Bowles, Pharm.D., MSc, FCCP Reviewed by Mary Beth O Connell, Pharm.D., FCCP, FASHP, BCPS; and Michelle M. Richardson, Pharm.D., FCCP, BCPS Learning Objectives 1. Apply
More informationEffect of breast cancer treatment
Effect of breast cancer treatment on the bones 1 Effect of breast cancer treatment on the bones This information is from the booklet Managing the late effects of breast cancer treatment. You may find the
More informationAmerican College of Rheumatology 2010 Recommendations for the Prevention and Treatment of
merican ollege of Rheumatology 2 Recommendations for the Prevention and Treatment of G L U O O R T I O I D - I N D U E D O S T E O P O R O S I S L I N I I N S G U I D E The objective of this guide is to
More informationNutrition for Family Living
Susan Nitzke, Nutrition Specialist; susan.nitzke@ces.uwex.edu Sherry Tanumihardjo, Nutrition Specialist; sherry.tan@ces.uwex.edu Amy Rettammel, Outreach Specialist; arettamm@facstaff.wisc.edu Betsy Kelley,
More informationDEFINITION OF OSTEOPOROSIS
CHAPTER 27 OSTEOPOROSIS AND OSTEOMALACIA DEFINITION OF OSTEOPOROSIS THE EPIDEMIOLOGY AND CONSEQUENCES OF OSTEOPOROSIS REVIEW OF BONE REMODELING BONE LOSS PATHOGENESIS OF OSTEOPOROSIS DIAGNOSIS OF OSTEOPOROSIS
More informationGo to Table of Contents. The Man s Guide. to Osteoporosis. National Osteoporosis Foundation
Go to Table of Contents The Man s Guide to Osteoporosis National Osteoporosis Foundation Contents Introduction... 2 Chapter 1: Start with bone healthy behaviors... 3 Get the calcium and vitamin D you need
More informationClinical Indicator Ages 19-29 Ages 30-39 Ages 40-49 Ages 50-64 Ages 65+ Frequency of visit as recommended by PCP
SCREENING EXAMINATION & COUNSELING UPMC Health Plan Clinical Indicator Ages 19-29 Ages 30-39 Ages 40-49 Ages 50-64 Ages 65+ Annually Physical Exam and Counseling 1 Blood Pressure 2 At each visit. At least
More informationNew Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine
New Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine Disclosures & Relevant Relationships I have nothing to disclose No financial conflicts Editor,
More informationMeasure #41: Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older National Quality Strategy Domain: Effective Clinical Care
Measure #41: Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS, REGISTRY
More informationX-Plain Vertebral Compression Fractures Reference Summary
X-Plain Vertebral Compression Fractures Reference Summary Introduction Back pain caused by a vertebral compression fracture, or VCF, is a common condition that affects thousands of people every year. A
More informationOsteoporosis and Vertebral Compression (Spinal) Fractures Fact Sheet
Osteoporosis and Vertebral Compression (Spinal) Fractures Fact Sheet About Osteoporosis Osteoporosis is estimated to affect 200 million women worldwide. 1 Worldwide, osteoporosis causes more than nine
More informationSponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,
More informationOsteoporosis/Bone Health in Adults as a National Public Health Priority
Position Statement Osteoporosis/Bone Health in Adults as a National Public Health Priority This Position Statement was developed as an educational tool based on the opinion of the authors. It is not a
More informationVITAMIN D PRODUCTS -WHAT AND WHEN TO PRESCRIBE. Claudette Allerdyce Principal Pharmacist Croydon CCG Pharmacy Team
VITAMIN D PRODUCTS -WHAT AND WHEN TO PRESCRIBE Claudette Allerdyce Principal Pharmacist Croydon CCG Pharmacy Team WHAT ARE THE ISSUES? A lack of suitable licensed vitamin D products in the UK for treating
More informationWOMENCARE A Healthy Woman is a Powerful Woman (407) 898-1500. Hormone Therapy
Hormone Therapy WOMENCARE A Healthy Woman is a Powerful Woman (407) 898-1500 At menopause, a woman's body makes less estrogen and she stops having menstrual periods. This is a natural stage in a woman's
More informationPreventive Care Recommendations THE BASIC FACTS
Preventive Care Recommendations THE BASIC FACTS MULTIPLE SCLEROSIS Carlos Healey, diagnosed in 2001 The Three Most Common Eye Disorders in Multiple Sclerosis Blood Pressure & Pulse Height & Weight Complete
More informationOsteoporosis: The patient s perspective. Claire Severgnini Chief Executive
Osteoporosis: The patient s perspective Claire Severgnini Chief Executive 1 Osteoporosis A long-term condition, mainly affecting people in later life Bones are fragile and more likely to fracture easily
More informationOsteoporosis. Am I at Risk?
Osteoporosis Am I at Risk? TABLE OF CONTENTS What is osteoporosis?...1 Who gets osteoporosis?...2 How can I prevent osteoporosis?...3 How do I know if I have osteoporosis?...4 What is a bone mineral density
More informationScreening Mammography for Breast Cancer: American College of Preventive Medicine Practice Policy Statement
Screening Mammography for Breast Cancer: American College of Preventive Medicine Practice Policy Statement Rebecca Ferrini, MD, Elizabeth Mannino, MD, Edith Ramsdell, MD and Linda Hill, MD, MPH Burden
More informationCrohn s Disease. From research to bedside
Crohn s Disease From research to bedside Primary Care Of The Crohn s Disease Patient Primary Physician s Concerns Vaccination Cancer Cervical Skin Osteoporosis Problems Associated With Vaccinating The
More informationMedications to Prevent and Treat Osteoporosis
Medications to Prevent and Treat Osteoporosis National Institutes of Health Osteoporosis and Related Bone Diseases ~ National Resource Center 2 AMS Circle Bethesda, MD 20892-3676 Tel: (800) 624-BONE or
More informationCompliance with drug therapies for the treatment and prevention of osteoporosis
Maturitas 48 (2004) 271 287 Compliance with drug therapies for the treatment and prevention of osteoporosis Jeffrey S. McCombs a,, Patrick Thiebaud b, Connie McLaughlin-Miley c, Jinhai Shi c a Department
More informationBone Mineral Density Studies
Bone Mineral Density Studies Policy Number: 6.01.01 Last Review: 5/2015 Origination: 10/1988 Next Review: 5/2016 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for bone
More informationDenosumab (Prolia) for postmenopausal osteoporosis
Denosumab (Prolia) for postmenopausal osteoporosis This Medicine Update is for women who are using, or thinking about using, denosumab. Summary Denosumab is a new medicine for women with osteoporosis.
More information